IOL Chemicals Reports Highest-Ever Quarterly Revenue, EBITDA & PAT

IOL Chemicals & Pharmaceuticals Ltd. announced its Unaudited Financial Results for Q2 & H1 FY27, reporting its highest-ever quarterly Revenue, EBITDA, and PAT. For Q2 FY27, Revenue from Operations stood at ₹795.0 Cr (up 20.1% YoY), EBITDA at ₹114.9 Cr (up 79.6% YoY), and PAT at ₹65.0 Cr (up 116.8% YoY). H1 FY27 also showed strong growth with Revenue at ₹1551.3 Cr (up 38.6% YoY), EBITDA at ₹226.6 Cr (up 69.7% YoY), and PAT at ₹129.5 Cr (up 102.5% YoY). The company highlighted the growing contribution of its non-Ibuprofen portfolio, which accounted for 45% of pharmaceutical revenue, and improved realisations in the Chemicals business.